"China is an important space for us and we see a major opportunity in China. As China opened, especially with the changes of regulations to the kind of products in terms of quality and cost-effective that we can build to China. "We are upgrading our team in China and we are also going to build a new plant very close to the current plant that we have. So overall, very exciting opportunities," Israeli further said.When contacted, Dr Reddy's spokesperson said the company generated approximately USD 130 million during the last fiscal and it is all through product sales. "And some will require a bio study and some will require a production by the relevant oncology plant in China, and those products have been put forth," he explained.

Source: Economic Times June 02, 2019 07:30 UTC